BioVie completes treatment phase of Phase 2 Long COVID trial for bezisterim
BIVI•Funding support
The trial is fully funded by a grant from the U.S. Department of War, limiting BioVie’s direct study funding exposure.
Phase 2 trial treatment phase completed
BioVie completed the treatment phase of its Phase 2 ADDRESS-LC trial of bezisterim for neurological Long COVID symptoms.
Topline results have not been presented; release is expected before the end of September 2026.
The readout is positioned as a test of bezisterim’s potential to ease fatigue and cognitive complaints linked to Long COVID.
